Kinoid of human tumor necrosis factor-alpha for rheumatoid arthritis

Bibliography

• Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum 2006;36(3):182-8
   PubMed Web of Science ®Google Scholar
• Detaille SI, Heerkens YF, Engels JA, Common prognostic factors of work disability among employees with a chronic somatic disease: a systematic review of cohort studies. Scand J Work Environ Health 2009;35(4):261-81
   PubMed Web of Science ®Google Scholar
• Myasoedova E, Gabriel SE. Cardiovascular disease in rheumatoid arthritis: a step forward. Curr Opin Rheumatol 2010;22(3):342-7
   PubMed Web of Science ®Google Scholar
• Franke LC, Ament AJ, van de Laar MA, Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009;27(4 Suppl 55):S118-23
   PubMed Web of Science ®Google Scholar
• EvaluatePharma. Therapeutic focus – anti-TNF market shows no sign of suppression. Available from: http://www.evaluatepharma.com/Universal/View.aspx?type=Story&id=185386&isEPVantage=yes 2009
   Google Scholar
• Koulinska I, Vasilakis-Scaramozza C, Crowell K. Rheumatoid Arthritis (Event Driven). Available from: http://decisionresources.com/Products-and-Services/Report.aspx?r=pcorim04xx 2010
   Google Scholar
• Datamonitor. Rheumatoid Arthritis Market Forecast. Available from: http://www.datamonitor.com/store/Product/rheumatoid_arthritis_market_forecast?productid=IMHC0215 2009
   Google Scholar
• Bongartz T, Sutton AJ, Sweeting MJ, Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295(19):2275-85
   PubMed Web of Science ®Google Scholar
• Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun 2010;11:180-210
   PubMedGoogle Scholar
• Russell AS. Quality-of-life assessment in rheumatoid arthritis. Pharmacoeconomics 2008;26(10):831-46
   PubMed Web of Science ®Google Scholar
• Bartelds GM, Wijbrandts CA, Nurmohamed MT, Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis 2010;69(5):817-21
   PubMed Web of Science ®Google Scholar
• Capini CJ, Bertin-Maghit SM, Bessis N, Active immunization against murine TNFalpha peptides in mice: generation of endogenous antibodies cross-reacting with the native cytokine and in vivo protection. Vaccine 2004;22(23-24):3144-53
   PubMed Web of Science ®Google Scholar
• Le Buanec H, Delavallee L, Bessis N, TNFalpha kinoid vaccination-induced neutralizing antibodies to TNFalpha protect mice from autologous TNFalpha-driven chronic and acute inflammation. Proc Natl Acad Sci USA 2006;103(51):19442-7
   PubMed Web of Science ®Google Scholar
• Radstake TR, Svenson M, Eijsbouts AM, Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009;68(11):1739-45
   PubMed Web of Science ®Google Scholar
• Chen YF, Jobanputra P, Barton P, A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006;10(42):iii-iv, xi-xiii, 1-229
   PubMedGoogle Scholar
• Delavallee L, Le Buanec H, Bessis N, Early and long-lasting protection from arthritis in tumour necrosis factor alpha (TNFalpha) transgenic mice vaccinated against TNFalpha. Ann Rheum Dis 2008;67(9):1332-8
   PubMed Web of Science ®Google Scholar
• Delavallee L, Semerano L, Assier E, Active immunization to tumor necrosis factor-alpha is effective in treating chronic established inflammatory disease: a long-term study in a transgenic model of arthritis. Arthritis Res Ther 2009;11(6):R195
   PubMed Web of Science ®Google Scholar
• Bizzini B, Drouet B, Zagury D, Kinoids: a family of immunogens for active anticytokine immunotherapy applied to autoimmune diseases and cancer. Immunotherapy 2010;2(3):347-65
   PubMed Web of Science ®Google Scholar
• Relyveld EH, Ben-Efraim S. Preparation of vaccines by the action of glutaraldehyde on toxins, bacteria, viruses, allergens, and cells. Methods Enzymol 1983;93:24-60
   PubMed Web of Science ®Google Scholar
• Bizzini B, Achour A. “Kinoids”: the basis for anticytokine immunization and their use in HIV infection. Cell Mol Biol (Noisy-le-grand) 1995;41(3):351-6
   PubMed Web of Science ®Google Scholar
• Harris JR, Markl J. Keyhole limpet hemocyanin (KLH): a biomedical review. Micron 1999;30(6):597-623
   PubMed Web of Science ®Google Scholar
• Yang L, Lindholm K, Konishi Y, Target depletion of distinct tumor necrosis factor receptor subtypes reveals hippocampal neuron death and survival through different signal transduction pathways. J Neurosci 2002;22(8):3025-32
   PubMed Web of Science ®Google Scholar
• Aucouturier J, Ascarateil S, Dupuis L. The use of oil adjuvants in therapeutic vaccines. Vaccine 2006;24(Suppl 2): S2-44-5
   PubMedGoogle Scholar
• Benji P, Burger F, Kruger D, Therapeutic immunization against TNF with a TNF-kinoid in Crohn's disease patients is safe and induces anti-TNF antibodies. In: Presented at: GASTRO2009 International Meeting UEGW/WCOG; 20 – 25 November 2009; London, UK
   Google Scholar